First-Line Management: Empirical PPI Trial
In an adult with persistent globus sensation and no alarm features, the first step in management is a 4-8 week trial of single-dose PPI therapy, as gastroesophageal reflux disease is a major underlying cause and this approach avoids unnecessary invasive testing in a benign condition 1, 2.
Rationale for Empirical PPI Therapy
The AGA guidelines explicitly recommend providing patients with troublesome reflux-related symptoms without alarm symptoms a 4-8 week trial of single-dose PPI therapy as first-line management 1. While these guidelines focus on classic GERD symptoms, the 2023 AGA update on extraesophageal GERD manifestations supports this approach for globus, recognizing GERD as a common etiology 2. Research confirms that empirical high-dose PPI therapy is reasonable given the benign nature of globus and GERD's role as a major causative factor 3.
When to Pursue This Approach
Empirical PPI therapy is appropriate when:
- No alarm features present: No dysphagia, odynophagia, weight loss, hematemesis, or progressive symptoms
- Isolated globus or globus with heartburn/regurgitation: Concomitant typical reflux symptoms strengthen the indication 4
- No urgent red flags on history: Patient anxiety about cancer is common (84% of patients) but does not necessitate immediate endoscopy in the absence of objective alarm features 5
Dosing and Duration
- Start with single-dose PPI once daily for 4-8 weeks 1
- If partial response, increase to twice-daily dosing or switch to a more effective acid suppressive agent 1
- Assess response at 4-8 weeks and taper to lowest effective dose if symptoms resolve 1
Important Caveats
Do not perform upfront endoscopy or laryngoscopy in isolated globus without alarm features. The AGA guidelines reserve upfront objective testing (rather than empirical PPI trial) specifically for isolated extraesophageal symptoms when there is high suspicion of reflux 1. However, for globus with typical reflux symptoms or when empirical therapy is reasonable, testing should be deferred 2.
Laryngoscopy findings (arytenoid erythema, vocal fold edema) lack specificity—these can occur in asymptomatic volunteers and do not confirm GERD causation 2. Similarly, endoscopy is normal in most GERD patients and does not establish causality for extraesophageal symptoms 2.
If PPI Trial Fails
After an adequate 4-8 week trial with dose escalation if needed:
- Consider nasolaryngoscopy to exclude structural pathology 4, 6
- Proceed to endoscopy if not already performed 4
- If both negative, consider pH monitoring off PPI (96-hour wireless preferred) to confirm or exclude GERD 1
- Explore alternative therapies: neuromodulation (SSRIs, low-dose tricyclics), cognitive-behavioral therapy, or speech therapy for persistent functional globus 7, 3
Reassurance is Therapeutic
Clinical assessment itself provides significant benefit—94.7% of globus patients report reassurance from the office visit 5. Explaining the benign nature of globus and the rationale for empirical therapy addresses the substantial anxiety (84% prevalence) that accompanies this symptom 5.